CDMO Costs & Pricing: What Actually Drives a Manufacturing Quote?

The frustrating answer is that there usually is not one useful number.

A Phase I biologics program, an API campaign, a sterile injectable product, an AAV vector, and a commercial tablet program are fundamentally different manufacturing projects.

Even two quotes for the same program can look very different because the CDMOs made different assumptions about scope.

That means comparing only the number at the bottom of the proposal can be misleading.

The better question is:

What are we actually paying this CDMO to do?

A manufacturing quote is built around the project.

Cost can be influenced by:

• modality
• development stage
• remaining development work
• manufacturing scale
• equipment
• raw materials
• analytical requirements
• project timing
• facility
• quality and documentation requirements
• number of batches
• packaging or drug product needs

A sponsor with a mature process requiring straightforward execution may receive a very different proposal from a sponsor that still needs substantial development.

One of the biggest pricing variables is how much work remains before manufacturing.

If the sponsor still needs:

• process development
• formulation work
• analytical methods
• scale-up
• technology transfer
• engineering batches

those activities will add scope.

A program arriving with a mature, transferable process may require less development work before GMP manufacturing begins.

That is why two programs using the same general technology can produce very different quotes.

A proposal becomes easier to understand when the sponsor can distinguish:

development costs

from

manufacturing costs

If those activities are bundled together without detail, comparing proposals becomes harder.

Sponsors should understand what development work the CDMO expects and what deliverables that work is intended to produce.

Larger production usually involves more materials and larger equipment.

But scale also changes other parts of the project.

It can affect:

• setup
• labor
• processing time
• analytical testing
• material handling
• facility utilization

The cheapest scale is not necessarily the smallest one.

Some facilities have minimum practical batch sizes that make very small campaigns inefficient.

Manufacturing requires more than CDMO labor and equipment.

Programs may depend on:

• raw materials
• reagents
• media
• resins
• components
• disposables
• containers and closures
• specialized starting materials

Sponsors should understand whether raw materials are:

• included in the quote
• estimated separately
• billed as pass-through costs
• subject to markup
• supplied by the sponsor

This is particularly important when materials are expensive or have long lead times.

Testing is sometimes underestimated when sponsors compare manufacturing quotes.

The project may require:

• method development
• method transfer
• in-process testing
• release testing
• stability testing
• specialized assays

Some CDMOs perform most testing internally.

Others outsource selected methods.

A lower manufacturing quote may not remain lower once analytical work is added.

A CDMO may need time to understand and receive the sponsor's process before manufacturing begins.

Technology-transfer costs can reflect:

• technical review
• document preparation
• method transfer
• equipment assessment
• project management
• development work
• engineering batches

Sponsors should know whether these activities are included in the proposal or billed separately.

A CDMO may recommend an engineering or non-GMP run before the GMP campaign.

That adds expense.

It may also identify process or equipment problems before a more expensive GMP batch.

The decision should therefore be evaluated as a risk-management question, not simply a cost line item.

A large commercial manufacturing facility may have a very different cost structure from a facility designed for smaller clinical programs.

The facility that can technically produce the product is not automatically the most economical choice.

Sponsors should compare whether the proposed site is appropriately sized and structured for the program.

Projects requiring specialized equipment or containment may cost more than more conventional manufacturing.

Examples can include:

• high-potency containment
• sterile filling
• lyophilization
• specialized vector production
• uncommon processing equipment

The relevant cost should be considered alongside the technical requirement that creates it.

An aggressive timeline may reduce flexibility in scheduling and procurement.

Rush work, limited manufacturing slots, expedited materials, or compressed development timelines can affect the commercial proposal.

Sponsors should be realistic about how schedule requirements influence cost.

The fastest possible route is not always the most economical one.

A drug substance quote may not include the cost of converting that material into the final product.

Depending on the program, additional scope may include:

• formulation
• fill finish
• lyophilization
• inspection
• labeling
• packaging
• storage
• shipping

Make sure proposals are being compared across the same manufacturing boundary.

Some CDMOs incorporate project management into the overall proposal.

Others show it as a distinct cost.

Sponsors should understand how project-management charges are structured and what support is included.

The important issue is not whether a line item exists.

It is whether the total scope is clear.

The original proposal is based on assumptions.

If the project changes, cost may change with it.

Examples include:

• additional development
• changed batch size
• new testing
• process modifications
• added manufacturing runs
• schedule changes

Sponsors should understand how scope changes are handled commercially.

A low initial quote can become expensive if the project requires repeated change orders.

Imagine two proposals:

CDMO A: $X

CDMO B: $X + 20%

At first glance, CDMO A looks cheaper.

But what if CDMO B includes analytical transfer, project management, stability, and engineering work while CDMO A excludes them?

The numbers cannot be meaningfully compared until the scope is normalized.

This creates a much better basis for comparison than looking only at the total.

Manufacturing cost and program cost are not always the same thing.

A cheaper CDMO may become more expensive if it results in:

• additional development
• repeated batches
• delayed manufacturing
• extra transfers
• extensive sponsor oversight

Likewise, the highest-priced CDMO is not automatically safer or better.

The goal is to understand the relationship between:

price + scope + technical fit + timeline + risk

Sponsors naturally have financial constraints.

Budget can help prioritize manufacturing options.

It should not be used to treat technically unsuitable manufacturers as viable simply because they appear cheaper.

PCN allows budget to be considered as part of project fit rather than automatically treating it as the only factor that determines whether a CDMO belongs on the shortlist.

A useful proposal should make important assumptions visible.

Sponsors should understand:

• what information the quote is based on
• what remains uncertain
• what could increase scope
• which activities are excluded
• how long the quote remains valid

That makes later comparison much more useful.

Pharma Connect Navigator helps sponsors narrow the manufacturing market before detailed commercial proposals begin.

Sponsors can define technical and operational requirements, including project budget considerations, and identify manufacturers that appear relevant to the program.

PCN helps teams compare project fit, facility information, capabilities, equipment, regulatory context, and other available factors before requesting deeper conversations.

That can reduce the likelihood of spending time collecting detailed pricing from manufacturers that were weak technical fits from the beginning.

PCN does not provide a universal manufacturing price or guarantee a quoted project cost.

Detailed commercial proposals must come from the CDMOs themselves.